Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 13/20 | 0.50 |
| ▸ | FNTB | P49356 | 13/20 | 0.50 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30052545 | 1.00 | FNTA (0.50) | FNTAFNTBPGGT1BLMNAALDH1A1 | |
| SCHEMBL11668382 | 0.97 | FNTA (0.47) | FNTAFNTBPGGT1BLMNAALDH1A1 | |
| SCHEMBL31026878 | 0.94 | FNTA (0.47) | FNTAFNTBPGGT1BLMNAMETAP2 | |
| SCHEMBL30051796 | 0.91 | FNTA (0.43) | FNTAFNTBPGGT1BLMNAALDH1A1 | |
| SCHEMBL30052878 | 0.91 | FNTA (0.48) | FNTAFNTBPGGT1BLMNARNPEP | |
| SCHEMBL30051389 | 0.90 | FNTA (0.46) | FNTAFNTBALDH1A1 | |
| SCHEMBL30051213 | 0.90 | FNTA (0.44) | FNTAFNTBALDH1A1 | |
| SCHEMBL34473997 | 0.90 | FNTA (0.58) | FNTAFNTBPGGT1BLMNA | |
| SCHEMBL30053022 | 0.90 | FNTA (0.50) | FNTAFNTBPGGT1BLMNA | |
| SCHEMBL30051582 | 0.90 | FNTA (0.58) | FNTAFNTBPGGT1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304178-A1 | Peptides and Their Use in the Treatment of Skin | AVON PRODUCTS, INC. | 2017-10-26 | — | — | US | disclosed |
| WO-2016105375-A1 | PEPTIDES AND THEIR USE IN THE TREATMENT OF SKIN | AVON PRODUCTS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304178-A1 | Peptides and Their Use in the Treatment of Skin | CUTA, IGFBP4, VIP | FNTA 3508/4885FNTB 3403/4885PGGT1B 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.